A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Therapy-Refractory Cutaneous AIDS-Related Kaposi's Sarcoma
Patients are given SU5416 via twice-weekly intravenous infusions in 4-week treatment cycles.
Any patient who has not experienced unacceptable toxicity and who is deemed to be responding
to the study drug (no evidence of disease progression) is permitted to continue receiving
SU5416 in 4-week treatment cycles (up to a maximum of 1 year of therapy) until that patient
experiences either unacceptable toxicity or tumor progression, as defined in the protocol.
Endpoint Classification: Efficacy Study, Primary Purpose: Treatment
United States: Food and Drug Administration
|Alison L. Hannah
|South San Francisco, California 94080